PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21787270-4	2011	We analyzed predictive markers of fluoropyrimidines effectiveness, principally for 5-Fluorouracil (5- FU) and also for oral fluoropyrimidines, as thymidylate Synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), methylenetetrahydrofolate reductase (MTHFR), deoxyuridine triphosphate nucleotidohydrolase (dUTPase), microsatellite instability.	fluoropyrimidines	34-51	methylenetetrahydrofolate reductase	Homo sapiens	255-290	
21787270-4	2011	We analyzed predictive markers of fluoropyrimidines effectiveness, principally for 5-Fluorouracil (5- FU) and also for oral fluoropyrimidines, as thymidylate Synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), methylenetetrahydrofolate reductase (MTHFR), deoxyuridine triphosphate nucleotidohydrolase (dUTPase), microsatellite instability.	fluoropyrimidines	34-51	methylenetetrahydrofolate reductase	Homo sapiens	292-297	
18034621-2	2007	Optimal cytotoxicity of fluoropyrimidines requires elevated CH(2)FH(4) tumoral concentrations, controlled by the methylenetetrahydrofolate reductase (MTHFR) enzyme, which irreversibly converts CH(2)FH(4) into 5-methyltetrahydrofolate.	fluoropyrimidines	24-41	methylenetetrahydrofolate reductase	Homo sapiens	113-148	
20368715-3	2011	Two polymorphisms were associated with TRG in a multivariate analysis: hOGG1-1245C > G, which can affect radiosensitivity and MTHFR-677C > T, which is involved in fluoropyrimidines action.	fluoropyrimidines	169-186	methylenetetrahydrofolate reductase	Homo sapiens	129-134	
18034621-2	2007	Optimal cytotoxicity of fluoropyrimidines requires elevated CH(2)FH(4) tumoral concentrations, controlled by the methylenetetrahydrofolate reductase (MTHFR) enzyme, which irreversibly converts CH(2)FH(4) into 5-methyltetrahydrofolate.	fluoropyrimidines	24-41	methylenetetrahydrofolate reductase	Homo sapiens	150-155	
12738713-5	2003	The aim of the present study was to investigate the association between the MTHFR polymorphism and response to 5-FU and other fluoropyrimidines in patients with metastatic colorectal cancer.	fluoropyrimidines	126-143	methylenetetrahydrofolate reductase	Homo sapiens	76-81	
17000685-2	2006	Genes for which polymorphisms may potentially influence pharmacodynamics of fluoropyrimidines, including capecitabine, are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD).	fluoropyrimidines	76-93	methylenetetrahydrofolate reductase	Homo sapiens	150-185	
17000685-2	2006	Genes for which polymorphisms may potentially influence pharmacodynamics of fluoropyrimidines, including capecitabine, are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD).	fluoropyrimidines	76-93	methylenetetrahydrofolate reductase	Homo sapiens	187-192	
30131855-1	2018	Methylenetetrahydrofolate reductase (MTHFR) is a critical enzyme influencing the metabolism of fluoropyrimidines.	fluoropyrimidines	95-112	methylenetetrahydrofolate reductase	Homo sapiens	0-35	
30131855-1	2018	Methylenetetrahydrofolate reductase (MTHFR) is a critical enzyme influencing the metabolism of fluoropyrimidines.	fluoropyrimidines	95-112	methylenetetrahydrofolate reductase	Homo sapiens	37-42